Completed PHASE2 INTERVENTIONAL 1-arm NCT00237380

Safety and Efficacy of Ataluren (PTC124) for Cystic Fibrosis

A Phase 2 Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis

Sponsor: PTC Therapeutics

Interventions Ataluren

Updated 6 times since 2017 Last updated: Jun 10, 2020 Started: Nov 30, 2005 Primary completion: May 31, 2006 Completion: May 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00237380, this PHASE2 trial focuses on Cystic Fibrosis and remains completed. Sponsored by PTC Therapeutics, it has been updated 6 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jul 2020 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Jul 2020 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

PTC Therapeutics

Data source: PTC Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jerusalem, Israel